(Q46368613)

21 December 2017

title

Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors (English)

1 reference

21 December 2017

author

Jens Juul Holst

series ordinal

1

1 reference

21 December 2017

author name string

C F Deacon

series ordinal

2

1 reference

21 December 2017

publication date

10 March 2005

1 reference

21 December 2017

published in

Diabetologia

1 reference

21 December 2017

volume

48

1 reference

21 December 2017

issue

4

1 reference

21 December 2017

page(s)

612-615

1 reference

21 December 2017

https://scigraph.springernature.com/pub.10.1007/s00125-005-1705-7

exact match

0 references

cites work

Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells

1 reference

12 December 2020

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes

1 reference

12 December 2020

Glucagon-like peptide containing pathways in the regulation of feeding behaviour

1 reference

12 December 2020

Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region.

1 reference

12 December 2020

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

1 reference

12 December 2020

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

1 reference

12 December 2020

Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms

1 reference

12 December 2020

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

1 reference

12 December 2020

Incretins, insulin secretion and Type 2 diabetes mellitus

1 reference

12 December 2020

The effect of glyburide on beta-cell sensitivity to glucose-dependent insulinotropic polypeptide.

1 reference

12 December 2020

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

1 reference

12 December 2020

Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor

1 reference

12 December 2020

The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1.

1 reference

12 December 2020

Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.

1 reference

12 December 2020

Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors

1 reference

12 December 2020

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

1 reference

12 December 2020

The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-1, but not to glucose-dependent insulinotropic polypeptide, in the portal vein

1 reference

12 December 2020

Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig

1 reference

12 December 2020

Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.

1 reference

12 December 2020

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

1 reference

12 December 2020

Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors

1 reference

12 December 2020

Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum

1 reference

12 December 2020

Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs

1 reference

12 December 2020

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

1 reference

12 December 2020

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

1 reference

12 December 2020

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

1 reference

12 December 2020

Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I

1 reference

12 December 2020

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

1 reference

12 December 2020

A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta cells

1 reference

12 December 2020

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

1 reference

12 December 2020

Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1

1 reference

12 December 2020

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

1 reference

12 December 2020

10.1007/S00125-005-1705-7

Identifiers

DOI

1 reference

21 December 2017

PubMed ID

15759106

1 reference

21 December 2017